Cantor Fitzgerald Comments on Bicara Therapeutics Inc.’s FY2024 Earnings (NASDAQ:BCAX)

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Research analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Bicara Therapeutics in a research report issued to clients and investors on Tuesday, October 8th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will earn ($1.61) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock.

BCAX has been the topic of a number of other research reports. TD Cowen began coverage on Bicara Therapeutics in a report on Tuesday. They set a “buy” rating on the stock. Stifel Nicolaus initiated coverage on Bicara Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $47.00 target price on the stock. Finally, Morgan Stanley began coverage on Bicara Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $35.00 price target for the company.

Bicara Therapeutics Trading Down 6.4 %

Shares of NASDAQ:BCAX opened at $19.00 on Thursday. Bicara Therapeutics has a fifty-two week low of $18.58 and a fifty-two week high of $27.94.

Insider Transactions at Bicara Therapeutics

In other news, major shareholder James E. Flynn bought 70,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the acquisition, the insider now directly owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Ra Capital Management, L.P. bought 1,833,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was acquired at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the purchase, the director now directly owns 4,303,418 shares of the company’s stock, valued at $77,461,524. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder James E. Flynn bought 70,000 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the acquisition, the insider now owns 897,587 shares of the company’s stock, valued at $16,156,566. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.